Form 4: 89bio Director Disposes Options in Roche Merger

89bio Director Derek DiRocco disposed of stock options as part of the company's acquisition by Roche Holdings, Inc., receiving cash and contingent value rights.

Summary

• 89bio, Inc. (ETNB) was acquired by Roche Holdings, Inc. ('Parent') and its subsidiary Bluefin Merger Subsidiary, Inc. ('Merger Sub') through an Agreement and Plan of Merger dated September 17, 2025.
• On October 30, 2025, Parent and Merger Sub completed a tender offer for all outstanding shares of 89bio common stock.
• The offer price was $14.50 per share in cash (the 'Closing Amount') plus one non-tradeable contingent value right ('CVR') per share, representing the right to receive up to an aggregate of $6.00 per share in cash upon achievement of specified milestones.
• Following the tender offer, Merger Sub merged into 89bio, with 89bio continuing as a wholly-owned subsidiary of Parent.
• As a result of the merger, all outstanding stock options to purchase 89bio shares became fully vested and exercisable.
• Options not exercised prior to the merger were cancelled and converted into the right to receive cash equal to the product of (A) the excess of the Closing Amount over the option's exercise price and (B) the number of shares subject to the option, plus one CVR per share.
• Options with an exercise price equal to or greater than the Closing Amount ($14.50) but less than $20.50 ('Out of the Money Options') were converted into the right to receive only the CVRs, with potential cash payments tied to milestone achievements exceeding the exercise price.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment of the Closing Amount or CVR.
• Derek DiRocco, a Director of 89bio, disposed of multiple stock options on October 30, 2025, as part of this merger transaction.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the company successfully completed a merger, providing a cash payout and potential future value through CVRs to shareholders and eligible option holders. However, the non-tradeable nature and contingency of CVRs, along with the cancellation of certain out-of-the-money options, temper the overall positive sentiment.

Positives

• The completion of the merger provides immediate cash value of $14.50 per share to 89bio shareholders and option holders (for in-the-money options).
• Shareholders and eligible option holders also received Contingent Value Rights (CVRs) offering potential additional payments of up to $6.00 per share, providing upside potential based on future milestones.
• The transaction represents a successful exit for 89bio, becoming part of a major pharmaceutical company, Roche Holdings, Inc.

Negatives

• Stock options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in no value for those specific options.
• The CVRs are non-tradeable, limiting liquidity for the contingent payments.
• The contingent payments from CVRs are not guaranteed and depend on the achievement of specified milestones by certain dates.

Risks

• The Contingent Value Rights (CVRs) are non-tradeable, meaning holders cannot sell them on the open market.
• Payments from CVRs are contingent upon the achievement of specified milestones on or prior to applicable milestone outside dates, and there is no guarantee these milestones will be met.
• The aggregate amount of CVR payments is capped at $6.00 per share, limiting potential upside.

Future Outlook

89bio, Inc. is now a wholly-owned subsidiary of Roche Holdings, Inc. Future financial outcomes for former 89bio shareholders and option holders who received CVRs will depend on the achievement of specified milestones as outlined in the Contingent Value Rights Agreement.

Industry Context

This acquisition reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and intellectual property. Such mergers often provide an exit strategy for investors in the acquired company and strategic assets for the acquirer.

Related Party Transactions

• Derek DiRocco holds certain options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., through an arrangement with RA Capital Management, L.P. (the 'Adviser').
• DiRocco is obligated to turn over any net cash or stock received from these options to the Adviser, which will offset advisory fees owed by the Funds to the Adviser.
• DiRocco disclaims beneficial ownership of these specific options and underlying common stock due to this arrangement.

Stakeholder Impact

• Shareholders received $14.50 per share in cash and one CVR per share, providing immediate liquidity and potential future upside.
• Option holders received cash and/or CVRs, or had their options cancelled, depending on their option's exercise price relative to the merger consideration.
• The company's employees, particularly those with equity compensation, are impacted by the conversion of their options and the change in company ownership structure.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine if additional payments will be made to CVR holders.

Key Dates

Keywords

89bio, ETNB, Roche, Merger, Acquisition, Stock Option, Form 4, Insider Transaction, Contingent Value Right, CVR, Biotechnology, Pharmaceutical